肿瘤药学2025，Vol.15Issue(1)：10-20,11.DOI:10.3969/j.issn.2095-1264.2025.01.02
抗体偶联药物在妇科肿瘤中的研究进展
Research progress of antibody-drug conjugates in gynecological tumors
摘要
Abstract
Gynecological tumors,mainly cervical cancer,endometrial cancer and ovarian cancer,seriously affect wom-en's health.Prevention and treatment of gynecological tumors are important tasks in women's medical care.With the use of immunotherapy and poly ADP-ribose polymerase(PARP)inhibitors,significant progress has been made in the treatment of gynecological tumors,but the prognosis for patients with advanced,recurrent or metastatic gynecological tumors remains poor.At present,the treatment options for patients with relapse after multiline therapy are still limited,so it is still neces-sary to explore new treatment to improve the prognosis of these patients.Antibody-drug conjugates(ADCs)have both the high activity of traditional chemotherapy drugs and the high selectivity of targeted drugs.They not only have a strong killing effect on tumor cells,but also can avoid serious systemic toxicity,and thus higher effectiveness of therapy can be achieved based on appropriate target selection.Therefore,they have gradually become a research hotspot in recent years.At present,ADCs have made some achievements in the research and application of gynecological tumor treatment,but there are still many challenges to be faced.Bispecific ADCs as well as combination therapy with ADCs and other medicine may be new directions for development.This article will systematically review the progress of ADCs in gynecological oncology.关键词
抗体偶联药物/妇科肿瘤/宫颈癌/子宫内膜癌/卵巢癌/研究进展Key words
Antibody-drug conjugate/Gynecological tumor/Cervical cancer/Endometrial cancer/Ovarian cancer/Re-search progress分类
临床医学引用本文复制引用
陆佩瑶,陈丽华,向阳..抗体偶联药物在妇科肿瘤中的研究进展[J].肿瘤药学,2025,15(1):10-20,11.基金项目
中国医学科学院临床与转化医学研究专项(2023-I2M-C&T-B-037). （2023-I2M-C&T-B-037）
